Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00816231 · ClinicalTrials.gov registry record · NA
Drug /Cue Interactions In Alcohol-Tobacco Comorbidity
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 244
- Enrollment target
NCT00816231: Completed NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT00816231 is a NA study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 244 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00816231, a NA study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 244 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how people react to different combinations of alcohol and nicotine.
Primary Outcome
To assess cravings and psychophysiological reactivity elicited by alcohol, smoking, and neutral cues following acute intake of alcohol and nicotine among individuals across a broad range of alcohol and cigarette use patterns (Study 1).
Interventions
- OTHER Placebo
- BEHAVIORAL Tobacco
- OTHER Alcoholic Beverage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2006-05-08 |
| Est. Completion | 2019-06-20 |
| Phase | NA |
What the finished NCT00816231 record still lists
NCT00816231 is an interventional study that assigns participants to a tested intervention. The registered 244 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00816231 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00816231 about?
NCT00816231 is a clinical study titled "Drug /Cue Interactions In Alcohol-Tobacco Comorbidity". The purpose of this study is to determine how people react to different combinations of alcohol and nicotine.
What is the current status of trial NCT00816231?
This trial is currently completed. It is a NA study. The enrollment target is 244 participants. The study started on 2006-05-08. Estimated completion is 2019-06-20.
What interventions are being tested in trial NCT00816231?
The interventions under investigation include: Placebo (OTHER), Tobacco (BEHAVIORAL), Alcoholic Beverage (OTHER).
Who is sponsoring clinical trial NCT00816231?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00816231's enrollment target sits among peer trials
244 438th of 2000 higher than 1,563 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02227251 · 244 participants · Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT04317534 · 244 participants · Phase 2
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
- NCT04683250 · 244 participants · Phase 1
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
- NCT04686305 · 244 participants · Phase 1
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI